Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the study of fruquintinib combined with tislelizumab is displayed, with study information and results-related details. It indicates the study is terminated and no longer recruiting participants.SummaryDifference67%

- Check14 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error screen.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide banner announces NIH updates and says some content may use “Super Intelligence” (SI) instead of “Artificial Intelligence” (AI) during a transition.SummaryDifference1%

- Check29 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check35 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study content and navigation with a minimal header. This indicates the record is currently inaccessible due to access restrictions.SummaryDifference20%

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.